Vera Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Vera Therapeutics R&D Spending Growth & History (VERA)
Vera Therapeutics's r&d spending was $215.3M for fiscal 2025.
View full Vera Therapeutics company overviewVera Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $215.3M | $89.1M | +70.61% |
| 2024 | 2024-12-31 | $126.2M | $47.9M | +61.29% |
| 2023 | 2023-12-31 | $78.2M | $9.2M | +13.38% |
| 2022 | 2022-12-31 | $69.0M | $46.5M | +206.85% |
| 2021 | 2021-12-31 | $22.5M | −$22.7M | −50.26% |
| 2020 | 2020-12-31 | $45.2M | — | — |
Vera Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $60.1M | $1.9M | +3.24% |
| Q1 2026 | 2026-03-31 | $86.0M | $44.7M | +108.37% |
| Q4 2025 | 2025-12-31 | $59.3M | $26.0M | +77.86% |
| Q3 2025 | 2025-09-30 | $56.5M | $16.2M | +40.08% |
| Q2 2025 | 2025-06-30 | $58.2M | $28.9M | +98.54% |
| Q1 2025 | 2025-03-31 | $41.3M | $18.1M | +77.92% |
| Q4 2024 | 2024-12-31 | $33.3M | $12.6M | +60.43% |
| Q3 2024 | 2024-09-30 | $40.3M | $24.2M | +150.40% |
| Q2 2024 | 2024-06-30 | $29.3M | $13.1M | +80.59% |
| Q1 2024 | 2024-03-31 | $23.2M | −$1.9M | −7.60% |
| Q4 2023 | 2023-12-31 | $20.8M | −$5.9M | −22.08% |
| Q3 2023 | 2023-09-30 | $16.1M | −$3.6M | −18.09% |
| Q2 2023 | 2023-06-30 | $16.2M | $6.1M | +60.51% |
| Q1 2023 | 2023-03-31 | $25.1M | $12.6M | +100.08% |
| Q4 2022 | 2022-12-31 | $26.7M | $13.9M | +109.17% |
| Q3 2022 | 2022-09-30 | $19.7M | $16.1M | +451.52% |
| Q2 2022 | 2022-06-30 | $10.1M | $6.9M | +212.58% |
| Q1 2022 | 2022-03-31 | $12.5M | $9.6M | +328.00% |
| Q4 2021 | 2021-12-31 | $12.8M | −$27.1M | −67.99% |
| Q3 2021 | 2021-09-30 | $3.6M | $1.6M | +81.01% |
| Q2 2021 | 2021-06-30 | $3.2M | $1.3M | +65.56% |
| Q1 2021 | 2021-03-31 | $2.9M | $1.5M | +103.75% |
| Q4 2020 | 2020-12-31 | $39.8M | — | — |
| Q3 2020 | 2020-09-30 | $2.0M | — | — |
| Q2 2020 | 2020-06-30 | $2.0M | — | — |
| Q1 2020 | 2020-03-31 | $1.4M | — | — |
Vera Therapeutics r&d spending trends
Over the last five fiscal years, Vera Therapeutics's r&d spending increased from $45.2M to $215.3M, a change of $170.1M. The latest reported quarter, Q2 2026, shows $60.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vera Therapeutics source filings ↗